Supernus Pharmaceuticals Long Term Debt 2011-2024 | SUPN
Supernus Pharmaceuticals long term debt from 2011 to 2024. Long term debt can be defined as the sum of all long term debt fields.
Supernus Pharmaceuticals Annual Long Term Debt
(Millions of US $) |
| 2023 |
$ |
| 2022 |
$ |
| 2021 |
$379 |
| 2020 |
$362 |
| 2019 |
$345 |
| 2018 |
$329 |
| 2017 |
$ |
| 2016 |
$4 |
| 2015 |
$7 |
| 2014 |
$26 |
| 2013 |
$34 |
| 2012 |
$11 |
| 2011 |
$23 |
| 2010 |
$ |
Supernus Pharmaceuticals Quarterly Long Term Debt
(Millions of US $) |
| 2024-09-30 |
|
| 2024-06-30 |
|
| 2024-03-31 |
|
| 2023-12-31 |
|
| 2023-09-30 |
|
| 2023-06-30 |
|
| 2023-03-31 |
|
| 2022-12-31 |
|
| 2022-09-30 |
|
| 2022-06-30 |
|
| 2022-03-31 |
$400 |
| 2021-12-31 |
$379 |
| 2021-09-30 |
$375 |
| 2021-06-30 |
$370 |
| 2021-03-31 |
$366 |
| 2020-12-31 |
$362 |
| 2020-09-30 |
$377 |
| 2020-06-30 |
$372 |
| 2020-03-31 |
$349 |
| 2019-12-31 |
$345 |
| 2019-09-30 |
$341 |
| 2019-06-30 |
$337 |
| 2019-03-31 |
$333 |
| 2018-12-31 |
$329 |
| 2018-09-30 |
$326 |
| 2018-06-30 |
$322 |
| 2018-03-31 |
$318 |
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2017-06-30 |
$1 |
| 2017-03-31 |
$3 |
| 2016-12-31 |
$4 |
| 2016-09-30 |
$6 |
| 2016-06-30 |
$6 |
| 2016-03-31 |
$6 |
| 2015-12-31 |
$7 |
| 2015-09-30 |
$8 |
| 2015-06-30 |
$9 |
| 2015-03-31 |
$11 |
| 2014-12-31 |
$26 |
| 2014-09-30 |
$26 |
| 2014-06-30 |
$29 |
| 2014-03-31 |
$28 |
| 2013-12-31 |
$34 |
| 2013-09-30 |
$60 |
| 2013-06-30 |
$59 |
| 2013-03-31 |
$8 |
| 2012-12-31 |
$11 |
| 2012-09-30 |
$14 |
| 2012-06-30 |
$17 |
| 2012-03-31 |
$20 |
| 2011-12-31 |
$23 |
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.975B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
